AZN
Income statement / Annual
Last year (2023), AstraZeneca PLC's total revenue was $45.81 B,
an increase of 3.29% from the previous year.
In 2023, AstraZeneca PLC's net income was $5.96 B.
See AstraZeneca PLC’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$45.81 B
|
$44.35 B
|
$37.42 B
|
$26.62 B
|
$24.38 B
|
$22.09 B
|
$22.47 B
|
$23.00 B
|
$24.71 B
|
$26.10 B
|
| Cost of Revenue |
$8.27 B |
$12.39 B |
$12.44 B |
$5.30 B |
$4.92 B |
$4.94 B |
$4.32 B |
$4.13 B |
$4.65 B |
$5.84 B |
| Gross Profit |
$37.54 B |
$31.96 B |
$24.98 B |
$21.32 B |
$19.46 B |
$17.15 B |
$18.15 B |
$18.88 B |
$20.06 B |
$20.25 B |
| Gross Profit Ratio |
0.82 |
0.72 |
0.67 |
0.8 |
0.8 |
0.78 |
0.81 |
0.82 |
0.81 |
0.78 |
| Research and Development
Expenses |
$10.94 B
|
$9.76 B
|
$9.74 B
|
$5.99 B
|
$5.96 B
|
$5.93 B
|
$5.76 B
|
$5.89 B
|
$6.00 B
|
$5.58 B
|
| General & Administrative
Expenses |
$17.49 B
|
$0.00
|
$0.00
|
$0.00
|
$11.68 B
|
$0.00
|
$10.23 B
|
$9.41 B
|
$11.11 B
|
$13.00 B
|
| Selling & Marketing
Expenses |
$18.22 B
|
$18.96 B
|
$15.68 B
|
$11.69 B
|
$11.85 B
|
$10.36 B
|
$10.54 B
|
$9.74 B
|
$11.45 B
|
$13.32 B
|
| Selling, General &
Administrative Expenses |
$18.22 B
|
$18.96 B
|
$15.68 B
|
$11.69 B
|
$11.85 B
|
$10.36 B
|
$10.54 B
|
$9.74 B
|
$11.45 B
|
$13.32 B
|
| Other Expenses |
-$336.00 M |
-$514.00 M |
-$1.49 B |
-$1.53 B |
-$1.54 B |
-$650.00 M |
-$10.44 B |
-$9.74 B |
-$11.63 B |
-$13.76 B |
| Operating Expenses |
$28.82 B |
$28.20 B |
$23.92 B |
$16.16 B |
$16.27 B |
$13.77 B |
$14.47 B |
$13.97 B |
$15.95 B |
$18.12 B |
| Cost And Expenses |
$37.09 B |
$40.59 B |
$36.36 B |
$21.46 B |
$21.19 B |
$18.70 B |
$18.79 B |
$18.10 B |
$20.59 B |
$23.96 B |
| Interest Income |
$301.00 M |
$95.00 M |
$43.00 M |
$87.00 M |
$172.00 M |
$138.00 M |
$113.00 M |
$67.00 M |
$46.00 M |
$78.00 M |
| Interest Expense |
$1.59 B |
$1.35 B |
$1.30 B |
$1.31 B |
$1.43 B |
$1.42 B |
$1.51 B |
$1.38 B |
$1.08 B |
$963.00 M |
| Depreciation &
Amortization |
$4.93 B
|
$5.25 B
|
$4.10 B
|
$2.90 B
|
$2.78 B
|
$2.78 B
|
$2.45 B
|
$2.31 B
|
$2.85 B
|
$3.28 B
|
| EBITDA |
$13.91 B
|
$9.33 B
|
$7.57 B
|
$8.37 B
|
$7.02 B
|
$7.17 B
|
$6.77 B
|
$7.29 B
|
$7.00 B
|
$5.49 B
|
| EBITDA Ratio |
0.3 |
0.21 |
0.2 |
0.31 |
0.29 |
0.32 |
0.3 |
0.32 |
0.28 |
0.21 |
| Operating Income Ratio
|
0.18
|
0.08
|
0.03
|
0.19
|
0.12
|
0.15
|
0.16
|
0.21
|
0.17
|
0.08
|
| Total Other
Income/Expenses Net |
-$1.29 B
|
-$1.26 B
|
-$1.32 B
|
-$1.25 B
|
-$1.38 B
|
-$1.39 B
|
-$1.45 B
|
-$1.35 B
|
-$1.05 B
|
-$891.00 M
|
| Income Before Tax |
$6.90 B |
$2.50 B |
-$265.00 M |
$3.92 B |
$1.55 B |
$1.99 B |
$2.23 B |
$3.55 B |
$3.07 B |
$1.25 B |
| Income Before Tax Ratio
|
0.15
|
0.06
|
-0.01
|
0.15
|
0.06
|
0.09
|
0.1
|
0.15
|
0.12
|
0.05
|
| Income Tax Expense |
$938.00 M |
-$792.00 M |
-$380.00 M |
$772.00 M |
$321.00 M |
-$57.00 M |
-$641.00 M |
$146.00 M |
$243.00 M |
$11.00 M |
| Net Income |
$5.96 B |
$3.29 B |
$112.00 M |
$3.20 B |
$1.34 B |
$2.16 B |
$3.00 B |
$3.50 B |
$2.83 B |
$1.23 B |
| Net Income Ratio |
0.13 |
0.07 |
0 |
0.12 |
0.05 |
0.1 |
0.13 |
0.15 |
0.11 |
0.05 |
| EPS |
1.92 |
1.06 |
0.04 |
1.22 |
0.51 |
0.85 |
1.19 |
1.39 |
1.12 |
0.49 |
| EPS Diluted |
1.91 |
1.06 |
0.04 |
1.22 |
0.51 |
0.85 |
1.19 |
1.38 |
1.12 |
0.49 |
| Weighted Average Shares
Out |
$3.10 B
|
$3.10 B
|
$2.84 B
|
$2.62 B
|
$2.60 B
|
$2.53 B
|
$2.53 B
|
$2.53 B
|
$2.53 B
|
$2.52 B
|
| Weighted Average Shares
Out Diluted |
$3.12 B
|
$3.12 B
|
$2.85 B
|
$2.63 B
|
$2.60 B
|
$2.53 B
|
$2.53 B
|
$2.53 B
|
$2.53 B
|
$2.53 B
|
| Link |
|
|
|
|
|
|
|
|
|
|
